Sanmamed and Chen [30] have confirmed anti-PD/PD-L1 therapy as a clearest approach to the normalization of cancer immunotherapy; it can selectively repair the tumor-induced immune defect and restore immune activity in the TME without general immune activation [30]. The gene discussed is CD274; the disease is neoplasm.